Scientific background
Autoimmune disease arises when immune cells become inappropriately activated and sustain harmful inflammatory responses. Over time, this persistent immune dysregulation can drive chronic disease, tissue damage, and the long-term burden of incomplete control.
Serendo Therapeutics is developing a precision therapeutic approach designed to modulate intracellular pathways involved in pathological immune activation. By intervening closer to the mechanisms that help sustain disease-driving immune responses, we aim to support a more selective and durable therapeutic effect.
Technology highlights
- Upstream modulation: targets intracellular mechanisms involved in pathological immune activation.
- Precision potential: designed to modulate disease-driving responses more selectively.
- Broad relevance: applicable to immune pathways shared across autoimmune conditions.
- Small-molecule approach: supports scalable development and potential oral dosing.
Selected references: Norin et al., Nature Communications 2021; Malinova et al., EMBO Reports 2021; Yang LQ et al., International Journal of Rheumatic Diseases 2025